Humacyte names pharma industry veteran Carrie Cox as CEO, member of Board of Directors

RESEARCH TRIANGLE PARK, N.C., Sept. 7, 2010 - Humacyte, Inc., a pioneer in regenerative medicine, today announced the appointment of Carrie S. Cox as Chief Executive Officer and a member of the company's Board of Directors, effective Sept. 20, 2010. Cox, a 30-year veteran of the pharmaceutical industry, brings a wealth of experience to Humacyte at a time when the company is moving into its next exciting development phase.

Laura Niklason, M.D., Ph.D., founder of Humacyte, said, "We are clearly delighted to have an executive with the experience, leadership and sound business judgment of Carrie Cox to lead Humacyte at this important juncture in our company's history. Carrie is ideally qualified to oversee our ongoing product development efforts and lead us into commercialization of these much-needed treatment options for patients."

Cox most recently served as Executive Vice President and President, Global Pharmaceuticals, at Schering-Plough Corporation, from 2003 until its merger with Merck & Co., Inc., in November 2009. In that role, she was responsible for the company's global prescription pharmaceutical business, which generated about three-fourths of Schering-Plough's approximately $20 billion in annual sales. Prior to that position at Schering-Plough she held a similar role at Pharmacia Corporation. She currently serves on the Boards of Directors of Texas Instruments, Cardinal Health and Celgene. Cox has been named six times to FORTUNE Magazine's list of the "50 Most Powerful Women in Business."

"I am proud to join Humacyte and become part of creating the future of regenerative medicine," said Cox. "The break-through science being conducted at Humacyte may one day bring major benefits to patients, while also improving health outcomes and reducing costs."

About Humacyte
Humacyte , a privately held company, is primarily focused on developing products for vascular disease and for dermal filling and repair. The company uses its innovative and proprietary platform technology to engineer human, extracellular matrix-based tissues that can be shaped into tubes, sheets, or particulate conformations, with properties similar to native tissues. These can then be used in many specific applications, with the potential to significantly improve treatment outcomes for a variety of patients, including those with diabetes and on hemodialysis. The company's process uses a unique cell source, and its proprietary technologies are designed to result in off-the-shelf products that can be utilized in any patient.